Recent studies from the University of Southern Denmark indicate that Ozempic, a medication widely used for type 2 diabetes management, may significantly increase the risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can lead to severe visual impairment. This finding has prompted discussions about the necessary balance between managing diabetes and understanding potential side effects of medications. Despite the increased risk, experts emphasize that abandoning such treatments isn't recommended; instead, careful monitoring and risk management are advised. The dual nature of medical treatment, wherein patients must weigh benefits against risks, is underscored here as the effect of long-term use remains somewhat uncertain.